11) Bacterial/Viral/Toxin/Broad Spectrum Prophylaxis
Abstract
The ultimate protection of the warfighter is by pretreating the warfighter to withstand any biological threat with no adverse side effects from the pretreatment. Such pretreatment would enable the warfighter to work in a less restrictive environment, absent of any personal protective equipment allowing operation at peak performance. Investments in this Program Element supports de-risking of candidates for transition into advanced development and includes: manufacturing process development, pre-clinical studies for lead candidates to allow initiation of clinical work, regulatory science to support clinical initiation, animal model development for U.S. Food & Drug Administration (FDA) animal rule licensure, and Phase 1 clinical trials. Candidates transition into advanced development once the Phase 1 clinical trial is complete.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2024
- Source ID
- fd97026d3dd1d810b23a9b1b5104492f